Q3 Earnings Forecast for Arvinas Issued By Leerink Partnrs

Key Points

• Leerink Partners has revised its Q3 2025 earnings per share (EPS) forecast for Arvinas down from ($0.44) to ($0.76), maintaining a "Hold" rating on the stock.
• Arvinas reported a Q2 EPS of (\$0.84), which was better than analysts' expectations of (\$0.87), but its revenue for the quarter dropped 70.7% year-over-year.
• The stock has seen various analysts adjust their price targets, with a current consensus price target of $19.76, reflecting a mix of "buy" and "neutral" ratings from different firms.

Arvinas, Inc. (NASDAQ:ARVN - Free Report) - Equities researchers at Leerink Partnrs dropped their Q3 2025 earnings per share (EPS) estimates for shares of Arvinas in a research report issued to clients and investors on Wednesday, August 6th. Leerink Partnrs analyst A. Berens now forecasts that the company will post earnings per share of ($0.76) for the quarter, down from their prior forecast of ($0.44). Leerink Partnrs currently has a "Hold" rating on the stock. The consensus estimate for Arvinas' current full-year earnings is ($3.81) per share. Leerink Partnrs also issued estimates for Arvinas' Q4 2025 earnings at ($0.24) EPS, FY2025 earnings at ($0.72) EPS, FY2026 earnings at ($2.57) EPS and FY2027 earnings at ($2.89) EPS.

ARVN has been the topic of a number of other research reports. Morgan Stanley lowered their price objective on Arvinas from $12.00 to $11.00 and set an "equal weight" rating on the stock in a report on Friday, May 9th. Piper Sandler reissued an "overweight" rating and set a $14.00 price objective (down previously from $24.00) on shares of Arvinas in a report on Friday, May 2nd. BTIG Research set a $16.00 price objective on Arvinas and gave the company a "buy" rating in a report on Friday, May 2nd. The Goldman Sachs Group lowered their target price on Arvinas from $12.00 to $8.00 and set a "neutral" rating on the stock in a report on Friday, May 2nd. Finally, Citigroup lowered their target price on Arvinas from $10.00 to $9.50 and set a "neutral" rating on the stock in a report on Monday, May 5th. Ten analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $19.76.

Arvinas Stock Performance

Shares of NASDAQ ARVN opened at $6.29 on Monday. The firm has a market cap of $461.81 million, a price-to-earnings ratio of -6.23 and a beta of 2.22. The business's 50-day simple moving average is $7.52 and its 200-day simple moving average is $9.86. Arvinas has a 52 week low of $5.90 and a 52 week high of $29.61.

Arvinas (NASDAQ:ARVN - Get Free Report) last issued its quarterly earnings data on Wednesday, August 6th. The company reported ($0.84) EPS for the quarter, beating analysts' consensus estimates of ($0.87) by $0.03. The business had revenue of $22.40 million for the quarter, compared to analyst estimates of $34.42 million. Arvinas had a negative return on equity of 12.01% and a negative net margin of 19.47%. The firm's revenue for the quarter was down 70.7% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.49) EPS.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of ARVN. T. Rowe Price Investment Management Inc. acquired a new position in shares of Arvinas in the fourth quarter valued at $42,332,000. Alyeska Investment Group L.P. bought a new position in shares of Arvinas during the 1st quarter worth approximately $12,636,000. Vanguard Group Inc. lifted its position in shares of Arvinas by 18.4% during the 1st quarter. Vanguard Group Inc. now owns 8,362,200 shares of the company's stock worth $58,703,000 after buying an additional 1,299,639 shares during the period. Acadian Asset Management LLC lifted its position in shares of Arvinas by 791.1% during the 2nd quarter. Acadian Asset Management LLC now owns 1,427,832 shares of the company's stock worth $10,498,000 after buying an additional 1,267,593 shares during the period. Finally, Boxer Capital Management LLC bought a new position in shares of Arvinas during the 4th quarter worth approximately $20,294,000. 95.19% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Arvinas

In related news, CFO Andrew Saik sold 5,700 shares of the company's stock in a transaction on Tuesday, June 24th. The stock was sold at an average price of $7.61, for a total value of $43,377.00. Following the completion of the transaction, the chief financial officer directly owned 164,401 shares in the company, valued at approximately $1,251,091.61. This represents a 3.35% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders own 4.73% of the company's stock.

About Arvinas

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.